Drugs / BC3195
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06548672 | Jun 2024 → Apr 2027 expected | cancer of unknown primary site, metastatic malignant neoplasm | Biocity Biopharmaceutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05957471 | Jun 2023 → Jun 2025 | — | Biocity Biopharmaceutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07469774 | Mar 2026 → Dec 2027 expected | — | Biocity Biopharmaceutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC3195 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06548672 ↗ |
| Route | Intravenous | “receive BC3195 via intravenous (IV)” NCT05957471 ↗ |
| Target | CDH3 | “targeting CDH3 (calcium-dependent adhesion 3)” NCT06548672 ↗ |